BETHESDA, Md., May 13, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEXD) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today reported financial results for the three months ended March 31, 2011.
Recent and Upcoming Highlights
Financial Results for the Three Months Ended March 31, 2011The net loss for the first quarter of 2011 was $0.2 million or $0.10 per share, compared with a net loss for the first quarter of 2010 of $2.1 million or $1.25 per share. The narrowing of the net loss was attributed mainly to lower research and development expenses, and gain on settlement of obligations of $0.8 mil
|SOURCE Spherix Incorporated|
Copyright©2010 PR Newswire.
All rights reserved